On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Lilly closed out the year by snagging a key new approval for Zepbound in obstructive sleep apnea (OSA), making it the first ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

And why didn’t it cut off Russia’s natural gas earlier? By Marc SantoraAndrew Higgins and Stanley Reed A transnational pipeline was shut down on Wednesday after Kyiv refused to renew a ...

Lilly’s trial has enrolled more than 13,000 participants and is evaluating whether tirzepatide, the incretin drug it sells as ...

Driver Rams Pickup Into Crowd in New Orleans, Killing 10 LIVE Suspect Is Dead; F.B.I. Is Investigating as Terror Attack The suspect, who is dead after a shootout with ...

Healthline News reports on emerging research, new treatments, diet, exercise, and trending topics in health and wellness. All articles are written by our network of editors and contributors ...